secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2026-02-02T23:59:59+00:00
Accession:  0001104659-26-008925
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet's partner Ascletis reports positive Phase 3 open-label 52-week acne data for denifanstat
--------------------------------------------------------------------------------

- 240 subjects received oral denifanstat 50 mg once daily for up to 40 weeks; 52 weeks total for prior denifanstat patients.
- Denifanstat well tolerated: dry eye syndrome (5.5%) and dry skin (5.2%) most common TEAEs; no denifanstat-related SAEs.
- No AE-related discontinuations; only 1 grade 1 hair thinning resolved without dose change; no deaths.
- All efficacy endpoints (IGA, lesion counts) showed improvements beyond those seen at 12 weeks in the prior Phase 3 trial.
- Ascletis holds China rights; Sagimet retains ex-China rights for denifanstat (FASN inhibitor).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926008925/0001104659-26-008925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926008925/tm264534d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-008925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer